Veterinary-compounded Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) oral tablets specially formulated for feline use. An off-label, human-medication-based treatment increasingly used by specialists to manage Feline Leukaemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) in cats by suppressing viral replication and helping restore immune function.
Key Benefits
- Significantly reduces viral load in many FeLV and FIV-positive cats
- Improves quality of life: better appetite, weight gain, reduced secondary infections
- Can extend lifespan and turn some cats into healthy, non-progressive carriers
- Once-daily dosing makes long-term management practical
Active Ingredients
Bictegravir 10 mg + Emtricitabine 40 mg + Tenofovir Alafenamide 5 mg per tablet (tiny, palatable, or crushable)
Dosage
- Average adult cat (4-5 kg): 1 tablet once daily
- Exact dose calculated by weight and blood work - always under veterinary supervision
Administration
Give whole, hide in treat, or compound into flavoured liquid/chew for easier dosing.
Side Effects
- Mild gastrointestinal upset (vomiting, diarrheas) - usually resolves in first weeks
- Rare: kidney value changes (tenofovir component) - regular blood work required
- Very rare: lactic acidosis or bone density concerns with long-term use
IMPORTANCE
Blood work (CBC, chemistry panel, viral load PCR) every 3-6 months recommended.